Search

Your search keyword '"Scott A. Tomlins"' showing total 566 results

Search Constraints

Start Over You searched for: Author "Scott A. Tomlins" Remove constraint Author: "Scott A. Tomlins"
566 results on '"Scott A. Tomlins"'

Search Results

1. Integrative multi-region molecular profiling of primary prostate cancer in men with synchronous lymph node metastasis

2. Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit

3. Alterations in homologous recombination repair genes in prostate cancer brain metastases

4. Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

5. Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study

6. Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis – Value of Autopsy in a Case Report

7. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer

8. Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors

9. Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series

10. Detection of Somatic Copy Number Alterations in Cancer Using Targeted Exome Capture Sequencing

11. Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer

12. Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer

13. Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer

14. Molecular Concepts Analysis Links Tumors, Pathways, Mechanisms, and Drugs

15. Noninvasive Detection of TMPRSS2:ERG Fusion Transcripts in the Urine of Men with Prostate Cancer

16. Whole Transcriptome Amplification for Gene Expression Profiling and Development of Molecular Archives

17. Expression of the Platelet-Derived Growth Factor Receptor in Prostate Cancer and Treatment Implications with Tyrosine Kinase Inhibitors

18. Integrative clinical genomics of metastatic cancer.

19. Supplementary Data from Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications

20. Data from Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma

21. Supplementary Figures S1-2, Tables S1-3 from Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors

23. Supplementary Figures S1 - S6, Tables S1 - S2 from Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature

24. Supplementary Figures 1-5 from Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers

25. Supplementary Methods, Figure Legends, Figures 1 - 9, Tables 1 - 8 from Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma

26. Supplementary Tables from Identification of Targetable FGFR Gene Fusions in Diverse Cancers

27. Supplementary Figures from Identification of Targetable FGFR Gene Fusions in Diverse Cancers

28. Data from Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications

29. Data from Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers

30. Supplementary Tables 1-3 from Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers

31. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies

32. Relevance of pRB Loss in Human Malignancies

33. Supplementary Tables from Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

34. Supplementary Materials and Methods from The CARMA3–Bcl10–MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor–Positive Breast Cancer

36. Data from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer

37. Data from Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts

38. Data from Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

39. Supplementary Data from Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers

40. Figure S6 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

41. Supplementary material from Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer

42. Data from CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer

43. Table S6 from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

44. Data from The CARMA3–Bcl10–MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor–Positive Breast Cancer

45. Supplementary Table 2 from The CARMA3–Bcl10–MALT1 Signalosome Drives NFκB Activation and Promotes Aggressiveness in Angiotensin II Receptor–Positive Breast Cancer

47. Data from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

48. Supplementary Figures from Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

49. Supplementary Methods from The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development

50. Supplementary Data from Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States

Catalog

Books, media, physical & digital resources